Strategies using prebiotics/probiotics/antibiotics or fecal microbial transplants to correct gut dysbiosis in NAFLD may reduce inflammatory signals, repair intestinal barrier dysfunction (thereby lowering portal vein endotoxin levels), and boost endogenous production of beneficial mediators like FGFs, GLP‐1, and secondary bile acids. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.